. Author manuscript; available in PMC: 2016 Jan 31.

Published in final edited form as: Can J Diabetes. 2014 Oct 22;39(1):73–77. doi: 10.1016/j.jcjd.2014.06.005

Table 1.

Epidemiologic and clinical findings at baseline examination

	Oral anti-diabetic agents group n=46	Insulin therapy group n=49	p
Age (years)	66.4 ± 10.7	65.2 ± 9.3	0.545
Sex (M/F)	25/21	32/17
Duration of DM (years)	12.4 ± 8.6	15.9 ± 8.3	0.054
HbA1c (%)	7.2 ± 1.62	7.3 ± 0.96	0.774
Creatinine (mg/dL)	1.1 ± 0.72	1.63 ± 1.29	0.061
BMI (Kg/m²)	29.6 ± 5.45	32.3 ± 7.85	0.153
CKD – EPI (mL/min)	66.3 ± 23.2	45.4 ± 30.4	0.072
Hypertension (n)	38	46
SBP (mm Hg)	132.1 ± 19.5	140 ± 17.8	0.064
DBP (mm Hg)	74.6 ± 11.9	74.3 ± 10.7	0.886
PDR (n)	14	22
NPDR (n)	32	27

DM: diabetes mellitus; BMI: body mass index; CKD-EPI: chronic kidney disease epidemiology collaboration equation; SBP: systolic blood pressure; DBP: diastolic blood pressure; PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy.